Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab Resistant Recurrent Glioblastoma
Enrolling By Invitation
18 years - 99 years
All
Phase
2
10 participants needed
1 Location
Brief description of study
This is a multicenter, open-label, phase II trial of pembrolizumab plus re-irradiation among recurrent glioblastoma patients enrolled to two parallel, non-comparative treatment arms including patients who are bevacizumab naïve (Arm A, n=30) and patients who are bevacizumab-resistant (Arm B, n=30).
All subjects must have histologically confirmed World Health Organization (WHO) Grade IV glioblastoma. Participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma is made. Other WHO grade IV glial neoplasms such as gliosarcoma are NOT eligible.
Subjects for this study will be recruited from the patient population that present to the Department of
Neurosurgery at the Hospital of the University of Pennsylvania for evaluation and treatment of their
brain tumors.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: glioblastoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 831956
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
